Letter to the Editor
A closer look at the safety and effectiveness of modern PORT in stage III-N2 non-small cell lung cancer
Abstract
We appreciate the interest of Dr. Fiorica in our study (1). The optimal treatment of patients with stage III locally advanced non-small-cell lung cancer (NSCLC) is still debatable. Regarding the high incidences and poor treatment outcomes (2), there is gaining interest in an optimization of the multimodality treatment for these patients.
